NeurogesX (NGSX) 0.3795 0.00

NeurogesX, Inc.
(NGSX) 0.3795 0.00

Last Trade:	0.37	Day Range:	0.35 - 0.39
Trade Time:	08:05PM	52wk Range:	0.31 - 4.4699
Prev. Close:	0.37	Market Cap:	12.28M
Open:	0.365	Div Yield:
Volume:	38514	PE:	-0
EPS:	-1.85

The Latest On NGSX

NeurogesX Receives Determination Letter From NASDAQ; Not Regaining Compliance 4/20/12 4:06pm

NeurogesX Engages JSB-Partners to Execute Business Development Strategy 4/17/12 7:34am

Benzinga's Microcap Movers for Wednesday April 11, 2012 4/12/12 8:19am

Benzinga's Microcap Movers for Wednesday March 14, 2012 3/15/12 7:01am

NeurogesX' Stock Trading Halted Today Ahead of Drug Advisory Committee Meeting 2/9/12 8:04am

Ladenburg Thalmann Lowers PT on NeurogesX from $2.5 to $1.6 2/7/12 2:03pm

NeurogesX, Inc. Announces $3.0 Million Private Placement 2/1/12 9:45am

Benzinga's Microcap Movers for Monday January 30, 2012 1/30/12 10:24pm

NeurogesX Appoints Ronald Martell President and Chief Executive Officer 1/3/12 11:01am

NeurogesX Confirms FDA Advisory Committee to Review sNDA for Qutenza 8% Patch 12/15/11 3:41pm

NeurogesX Receives FDA Acceptance for Review of sNDA for Qutenza 8% Patch for HIV-Associated Peripheral Neuropathy 11/14/11 5:10pm

NeurogesX Reports Positive Phase 2 Results for NGX-1998 for Treatment of Postherpetic Neuralgia 11/8/11 8:23am

NeurogesX Receives Determination Letter From NASDAQ; Not Regaining Compliance 4/20/12

NeurogesX Engages JSB-Partners to Execute Business Development Strategy 4/17/12

Benzinga's Microcap Movers for Wednesday April 11, 2012 4/12/12

Benzinga's Microcap Movers for Wednesday March 14, 2012 3/15/12

NeurogesX' Stock Trading Halted Today Ahead of Drug Advisory Committee Meeting 2/9/12

Ladenburg Thalmann Lowers PT on NeurogesX from $2.5 to $1.6 2/7/12

NeurogesX, Inc. Announces $3.0 Million Private Placement 2/1/12

Benzinga's Microcap Movers for Monday January 30, 2012 1/30/12

NeurogesX Appoints Ronald Martell President and Chief Executive Officer 1/3/12

NeurogesX Confirms FDA Advisory Committee to Review sNDA for Qutenza 8% Patch 12/15/11

NeurogesX Receives FDA Acceptance for Review of sNDA for Qutenza 8% Patch for HIV-Associated Peripheral Neuropathy 11/14/11

NeurogesX Reports Positive Phase 2 Results for NGX-1998 for Treatment of Postherpetic Neuralgia 11/8/11

Benzinga's Microcap Movers for Wednesday April 11, 2012 4/12/12

Benzinga's Microcap Movers for Wednesday March 14, 2012 3/15/12

Benzinga's Microcap Movers for Monday January 30, 2012 1/30/12

Market Gives Up Gains Ahead of House Vote 7/28/11

Benzinga’s Top Pre- Market Gainers (EJ, ZOOM, SMTL, APWR, BPHX, NGSX, SINA, QCOR) 11/17/09

Ladenburg Thalmann Lowers PT on NeurogesX from $2.5 to $1.6 2/7/12

UPDATE: Ladenburg Thalmann Lowers PT on NeurogesX to $2.50 11/1/11

Ladenburg Thalmann Lowers PT on NeurogesX to $2.50 11/1/11

Wedbush Downgrades NeurogesX to Neutral, PT Lowered to $2 9/28/11

New PT For NGSX 9/28/10

Trade NGSX
NOW!

Partner Headlines

NeurogesX Inc. Reports Operating Results (10-Q) 5/10/12

NeurogesX Inc. Reports Operating Results (10-K) 3/29/12

NeurogesX Inc. Reports Operating Results (10-Q) 11/14/11

Insiders Trading TXI, P, NGSX, CNK 6/21/11

5 Health Care Stocks With Upside 3/21/11

10 Biotech Stocks Expected to at Least Double 10/19/10

Stock Offerings: Kodiak Oil & Gas 8/13/10

Press Releases

NeurogesX Reports First Quarter 2012 Results 5/3/12 GlobeNewswire

Robbins Umeda LLP Announces an Investigation of NeurogesX, Inc. 5/3/12 Business Wire

NeurogesX to Hold Conference Call to Discuss First Quarter 2012 Results 4/27/12 GlobeNewswire

The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in NeurogesX, Inc. of Class Action Lawsuit 4/23/12 Newswire

NeurogesX Receives Determination Letter From NASDAQ 4/20/12 GlobeNewswire

NeurogesX Engages JSB-Partners to Execute Business Development Strategy 4/17/12 GlobeNewswire

NeurogesX Provides Update on NGX-1998 Clinical Program 4/11/12 GlobeNewswire

NeurogesX Reports Fourth Quarter and Year-End 2011 Results 3/8/12 GlobeNewswire

NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Full Year 2011 Results 2/29/12 GlobeNewswire

NeurogesX Provides Update on Qutenza(R) (Capsaicin) 8% Patch for New Indication to Treat HIV-PN Following FDA Advisory Committee Review 2/9/12 GlobeNewswire

NeurogesX' Stock Trading Halted Today 2/9/12 GlobeNewswire

NeurogesX Grants Equity Awards Under Its 2011 Inducement Stock Plan 2/3/12 GlobeNewswire

Get the latest NGSX stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for NeurogesX, Inc. stock price.

NeurogesX, Inc. by YCharts

NeurogesX (NGSX) 0.3795 0.00

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On NGSX

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social